Cargando…

Niclosamide induces miR-148a to inhibit PXR and sensitize colon cancer stem cells to chemotherapy

Tumor recurrence is often attributed to cancer stem cells (CSCs). We previously demonstrated that down-regulation of Pregnane X Receptor (PXR) decreases the chemoresistance of CSCs and prevents colorectal cancer recurrence. Currently, no PXR inhibitor is usable in clinic. Here, we identify miR-148a...

Descripción completa

Detalles Bibliográficos
Autores principales: Bansard, Lucile, Bouvet, Océane, Moutin, Elisa, Le Gall, Gaétan, Giammona, Alessandro, Pothin, Elodie, Bacou, Marion, Hassen-Khodja, Cédric, Bordignon, Benoit, Bourgaux, Jean François, Prudhomme, Michel, Hollande, Frédéric, Pannequin, Julie, Pascussi, Jean Marc, Planque, Chris
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9023769/
https://www.ncbi.nlm.nih.gov/pubmed/35276090
http://dx.doi.org/10.1016/j.stemcr.2022.02.005
_version_ 1784690417503043584
author Bansard, Lucile
Bouvet, Océane
Moutin, Elisa
Le Gall, Gaétan
Giammona, Alessandro
Pothin, Elodie
Bacou, Marion
Hassen-Khodja, Cédric
Bordignon, Benoit
Bourgaux, Jean François
Prudhomme, Michel
Hollande, Frédéric
Pannequin, Julie
Pascussi, Jean Marc
Planque, Chris
author_facet Bansard, Lucile
Bouvet, Océane
Moutin, Elisa
Le Gall, Gaétan
Giammona, Alessandro
Pothin, Elodie
Bacou, Marion
Hassen-Khodja, Cédric
Bordignon, Benoit
Bourgaux, Jean François
Prudhomme, Michel
Hollande, Frédéric
Pannequin, Julie
Pascussi, Jean Marc
Planque, Chris
author_sort Bansard, Lucile
collection PubMed
description Tumor recurrence is often attributed to cancer stem cells (CSCs). We previously demonstrated that down-regulation of Pregnane X Receptor (PXR) decreases the chemoresistance of CSCs and prevents colorectal cancer recurrence. Currently, no PXR inhibitor is usable in clinic. Here, we identify miR-148a as a targetable element upstream of PXR signaling in CSCs, which when over-expressed decreases PXR expression and impairs tumor relapse after chemotherapy in mouse tumor xenografts. We then develop a fluorescent reporter screen for miR-148a activators and identify the anti-helminthic drug niclosamide as an inducer of miR-148a expression. Consequently, niclosamide decreased PXR expression and CSC numbers in colorectal cancer patient-derived cell lines and synergized with chemotherapeutic agents to prevent CSC chemoresistance and tumor recurrence in vivo. Our study suggests that endogenous miRNA inducers is a viable strategy to down-regulate PXR and illuminates niclosamide as a neoadjuvant repurposing strategy to prevent tumor relapse in colon cancer.
format Online
Article
Text
id pubmed-9023769
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-90237692022-04-23 Niclosamide induces miR-148a to inhibit PXR and sensitize colon cancer stem cells to chemotherapy Bansard, Lucile Bouvet, Océane Moutin, Elisa Le Gall, Gaétan Giammona, Alessandro Pothin, Elodie Bacou, Marion Hassen-Khodja, Cédric Bordignon, Benoit Bourgaux, Jean François Prudhomme, Michel Hollande, Frédéric Pannequin, Julie Pascussi, Jean Marc Planque, Chris Stem Cell Reports Article Tumor recurrence is often attributed to cancer stem cells (CSCs). We previously demonstrated that down-regulation of Pregnane X Receptor (PXR) decreases the chemoresistance of CSCs and prevents colorectal cancer recurrence. Currently, no PXR inhibitor is usable in clinic. Here, we identify miR-148a as a targetable element upstream of PXR signaling in CSCs, which when over-expressed decreases PXR expression and impairs tumor relapse after chemotherapy in mouse tumor xenografts. We then develop a fluorescent reporter screen for miR-148a activators and identify the anti-helminthic drug niclosamide as an inducer of miR-148a expression. Consequently, niclosamide decreased PXR expression and CSC numbers in colorectal cancer patient-derived cell lines and synergized with chemotherapeutic agents to prevent CSC chemoresistance and tumor recurrence in vivo. Our study suggests that endogenous miRNA inducers is a viable strategy to down-regulate PXR and illuminates niclosamide as a neoadjuvant repurposing strategy to prevent tumor relapse in colon cancer. Elsevier 2022-03-10 /pmc/articles/PMC9023769/ /pubmed/35276090 http://dx.doi.org/10.1016/j.stemcr.2022.02.005 Text en © 2022 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Bansard, Lucile
Bouvet, Océane
Moutin, Elisa
Le Gall, Gaétan
Giammona, Alessandro
Pothin, Elodie
Bacou, Marion
Hassen-Khodja, Cédric
Bordignon, Benoit
Bourgaux, Jean François
Prudhomme, Michel
Hollande, Frédéric
Pannequin, Julie
Pascussi, Jean Marc
Planque, Chris
Niclosamide induces miR-148a to inhibit PXR and sensitize colon cancer stem cells to chemotherapy
title Niclosamide induces miR-148a to inhibit PXR and sensitize colon cancer stem cells to chemotherapy
title_full Niclosamide induces miR-148a to inhibit PXR and sensitize colon cancer stem cells to chemotherapy
title_fullStr Niclosamide induces miR-148a to inhibit PXR and sensitize colon cancer stem cells to chemotherapy
title_full_unstemmed Niclosamide induces miR-148a to inhibit PXR and sensitize colon cancer stem cells to chemotherapy
title_short Niclosamide induces miR-148a to inhibit PXR and sensitize colon cancer stem cells to chemotherapy
title_sort niclosamide induces mir-148a to inhibit pxr and sensitize colon cancer stem cells to chemotherapy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9023769/
https://www.ncbi.nlm.nih.gov/pubmed/35276090
http://dx.doi.org/10.1016/j.stemcr.2022.02.005
work_keys_str_mv AT bansardlucile niclosamideinducesmir148atoinhibitpxrandsensitizecoloncancerstemcellstochemotherapy
AT bouvetoceane niclosamideinducesmir148atoinhibitpxrandsensitizecoloncancerstemcellstochemotherapy
AT moutinelisa niclosamideinducesmir148atoinhibitpxrandsensitizecoloncancerstemcellstochemotherapy
AT legallgaetan niclosamideinducesmir148atoinhibitpxrandsensitizecoloncancerstemcellstochemotherapy
AT giammonaalessandro niclosamideinducesmir148atoinhibitpxrandsensitizecoloncancerstemcellstochemotherapy
AT pothinelodie niclosamideinducesmir148atoinhibitpxrandsensitizecoloncancerstemcellstochemotherapy
AT bacoumarion niclosamideinducesmir148atoinhibitpxrandsensitizecoloncancerstemcellstochemotherapy
AT hassenkhodjacedric niclosamideinducesmir148atoinhibitpxrandsensitizecoloncancerstemcellstochemotherapy
AT bordignonbenoit niclosamideinducesmir148atoinhibitpxrandsensitizecoloncancerstemcellstochemotherapy
AT bourgauxjeanfrancois niclosamideinducesmir148atoinhibitpxrandsensitizecoloncancerstemcellstochemotherapy
AT prudhommemichel niclosamideinducesmir148atoinhibitpxrandsensitizecoloncancerstemcellstochemotherapy
AT hollandefrederic niclosamideinducesmir148atoinhibitpxrandsensitizecoloncancerstemcellstochemotherapy
AT pannequinjulie niclosamideinducesmir148atoinhibitpxrandsensitizecoloncancerstemcellstochemotherapy
AT pascussijeanmarc niclosamideinducesmir148atoinhibitpxrandsensitizecoloncancerstemcellstochemotherapy
AT planquechris niclosamideinducesmir148atoinhibitpxrandsensitizecoloncancerstemcellstochemotherapy